First, we analyzed DPYSL5 mRNA expression in the NEPC patient cohort from  Beltran et al. 20165 and identified exclusively high DPYSL5 mRNA levels in clinical NEPC samples compared to prostate adenocarcinoma (Fig. 1a). Here, DPYSL5 is linked to prostate adenocarcinoma.